Cryoport, Inc. (CYRX)

Cryoport, Inc. (CYRX) Industrial Operations Profile

Cryoport, Inc. delivers temperature-controlled logistics solutions for the life sciences, leveraging its Cryoportal platform and specialized shipping containers. Serving biopharma, animal health, and human reproductive medicine, the company ensures the integrity of biological materials across the Americas, EMEA, and APAC regions, distinguishing itself through comprehensive logistics management and regulatory compliance.

What Is the Investment Thesis for CYRX?

Cryoport's investment thesis rests on its critical role in the rapidly growing biopharma and life sciences sectors, where the secure and temperature-controlled transport of biological materials is paramount. With a P/E ratio of 6.7 and a profit margin of 43.9%, the company demonstrates strong profitability. The company's Cryoportal platform and specialized shipping solutions create a competitive advantage, ensuring regulatory compliance and real-time monitoring. Growth catalysts include the increasing demand for cell and gene therapies, which rely heavily on Cryoport's services. The company's expansion into new geographic markets and service offerings also presents significant growth opportunities. However, potential risks include increased competition in the temperature-controlled logistics market and regulatory changes that could impact the company's operations. Investors should monitor Cryoport's ability to maintain its market share and adapt to evolving industry standards.

Based on FMP financials and quantitative analysis

CYRX Key Highlights

• Market capitalization of $776.20M reflects investor valuation of Cryoport's market position.
• P/E ratio of 6.7 indicates the company's earnings relative to its stock price.
• Profit margin of 43.9% demonstrates strong profitability in the life sciences logistics sector.
• Gross margin of 47.2% highlights efficient cost management in service delivery.
• Beta of 1.69 suggests higher volatility compared to the overall market.

Who Are CYRX's Competitors?

CYRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CYRX's Key Strengths?

• Specialized expertise in temperature-controlled logistics for the life sciences.
• Proprietary Cryoportal platform for managing complex shipments.
• Strong relationships with leading biopharmaceutical companies.
• Global network of logistics partners and facilities.

What Are CYRX's Weaknesses?

• High dependence on the biopharma industry.
• Limited diversification beyond temperature-controlled logistics.
• Potential for disruptions in the supply chain.
• Exposure to regulatory changes in the life sciences industry.

What Could Drive CYRX Stock Higher?

• Increasing demand for cell and gene therapies driving demand for Cryoport's services.
• Expansion into new geographic markets, particularly in Asia Pacific and Latin America.
• Potential acquisitions of complementary businesses to expand service offerings.
• Development and implementation of advanced monitoring technologies for enhanced logistics solutions.

What Are the Key Risks for CYRX?

• Financial-distress signal — its Altman Z-Score of 0.95 sits in the distress zone (elevated bankruptcy risk).
• Increased competition from traditional freight companies and specialized logistics providers.
• Economic downturns impacting the biopharma industry and reducing demand for logistics services.
• Regulatory changes affecting the transport of biological materials.
• Cybersecurity threats targeting sensitive shipment data and disrupting operations.

What Are the Growth Opportunities for CYRX?

• Expansion into Emerging Markets: Cryoport has the opportunity to expand its services into emerging markets in Asia Pacific and Latin America, where the biopharma industry is rapidly growing. These regions present a significant untapped market for temperature-controlled logistics, driven by increasing healthcare investments and the adoption of advanced therapies. This expansion could increase revenue by 15-20% over the next three years.
• Increased Adoption of Cell and Gene Therapies: The increasing adoption of cell and gene therapies presents a significant growth opportunity for Cryoport. These therapies require precise temperature control during manufacturing, storage, and transport, creating a high demand for Cryoport's specialized logistics solutions. As more cell and gene therapies receive regulatory approval and become commercially available, Cryoport is well-positioned to capitalize on this trend, potentially increasing revenue by 25% in the next five years.
• Strategic Acquisitions: Cryoport can pursue strategic acquisitions to expand its service offerings and geographic reach. Acquiring companies with complementary capabilities, such as specialized packaging or last-mile delivery services, can enhance Cryoport's value proposition and strengthen its competitive position. These acquisitions could lead to a 10-15% increase in market share within two years.
• Development of Advanced Monitoring Technologies: Investing in the development of advanced monitoring technologies can further enhance Cryoport's logistics solutions. Real-time temperature and location tracking, coupled with predictive analytics, can provide greater visibility and control over shipments, reducing the risk of temperature excursions and ensuring the integrity of biological materials. This technology could attract premium clients willing to pay more for enhanced security and reliability.
• Partnerships with Biopharma Companies: Establishing strategic partnerships with biopharma companies can provide Cryoport with a steady stream of business and enhance its reputation as a trusted logistics provider. These partnerships can involve long-term contracts for temperature-controlled logistics services, as well as collaboration on the development of new solutions to meet the evolving needs of the biopharma industry. Such partnerships could secure long-term revenue streams and increase customer loyalty.

What Opportunities Does CYRX Have?

• Expansion into emerging markets with growing biopharma industries.
• Increased adoption of cell and gene therapies driving demand for specialized logistics.
• Strategic acquisitions to expand service offerings and geographic reach.
• Development of advanced monitoring technologies to enhance logistics solutions.

What Threats Does CYRX Face?

• Increased competition from traditional freight companies and specialized logistics providers.
• Economic downturns impacting the biopharma industry.
• Regulatory changes affecting the transport of biological materials.
• Cybersecurity threats targeting sensitive shipment data.

What Are CYRX's Competitive Advantages?

• Specialized Expertise: Deep understanding of the specific requirements for transporting biological materials.
• Proprietary Technology: Cryoportal platform provides a competitive advantage in managing complex logistics.
• Regulatory Compliance: Expertise in navigating complex regulatory requirements for the life sciences industry.
• Global Network: Extensive network of logistics partners and facilities across the Americas, EMEA, and APAC.

What Does CYRX Do?

Founded in 1999 and headquartered in Brentwood, Tennessee, Cryoport, Inc. has established itself as a leading provider of temperature-controlled logistics solutions for the life sciences industry. The company's core mission is to ensure the safe and reliable transport of biological materials, catering to the specific needs of the biopharma/pharma, animal health, and human reproductive medicine markets. Cryoport operates across the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions. Cryoport's key offering is the Cryoportal, a cloud-based logistics management platform that facilitates the seamless management of shipments. This platform supports various critical functions, including order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and adherence to regulatory compliance requirements. Complementing the Cryoportal is the CryoPort Express Shippers, which are specialized containers designed to maintain the stability of shipped biologic commodities throughout the entire shipping cycle. The company also provides information dashboards and validation documentation through the SmartPak Condition Monitoring System, which collects data on shipments. In addition to its logistics platform and shipping solutions, Cryoport offers a range of related services, including biological specimen cryopreservation storage and maintenance, archiving, monitoring, tracking, receipt, and delivery of samples. The company also provides transportation of frozen biological specimens to and from customer locations, along with logistics support and management. Furthermore, Cryoport offers short-term logistics and engineering consulting services, providing comprehensive support to its clients in the life sciences industry.

What Products and Services Does CYRX Offer?

• Provides temperature-controlled logistics solutions for the life sciences industry.
• Offers the Cryoportal, a cloud-based platform for managing shipments of biological materials.
• Manufactures and supplies CryoPort Express Shippers to maintain the stability of biological commodities.
• Offers biological specimen cryopreservation storage and maintenance services.
• Transports frozen biological specimens to and from customer locations.
• Provides logistics support and management for incoming and outgoing biological specimens.
• Offers short-term logistics and engineering consulting services.

How Does CYRX Make Money?

• Provides logistics services for biopharma, animal health, and human reproductive medicine markets.
• Generates revenue through shipping fees, storage fees, and consulting services.
• Offers a subscription-based model for access to the Cryoportal platform.
• Sells CryoPort Express Shippers and related products.

What Industry Does CYRX Operate In?

Cryoport operates within the integrated freight and logistics industry, specifically catering to the life sciences sector. The market for temperature-controlled logistics is experiencing substantial growth, driven by the increasing demand for biopharmaceuticals, cell and gene therapies, and personalized medicine. These therapies require precise temperature control during transport to maintain their efficacy and viability. Cryoport's competitive landscape includes specialized logistics providers and traditional freight companies that offer temperature-controlled services. The company differentiates itself through its focus on the life sciences, its proprietary Cryoportal platform, and its expertise in handling sensitive biological materials.

Who Are CYRX's Key Customers?

• Biopharmaceutical companies developing and manufacturing cell and gene therapies.
• Animal health companies involved in the research and development of veterinary medicines.
• Human reproductive medicine clinics and research centers.
• Hospitals and research institutions conducting clinical trials.

Company Profile

Cryoport, Inc. operates in the Integrated Freight & Logistics industry within the Industrials sector. It is headquartered in Brentwood, US. The company is led by CEO Jerrell W. Shelton. CYRX has traded publicly since 2005.

ROE 16%Key Financial Metrics

Return on equity for Cryoport, Inc. stands at 16.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 10.1%, showing how much profit it generates from its asset base. CYRX trades at a trailing price-to-earnings ratio of 6.74, below the Industrials sector average of ~30x. Its free cash flow yield is -3.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.09 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 9.8%, the inverse of the P/E and a quick read on earnings relative to price.

CYRX Valuation & Market Position

With a $776.20M market cap, Cryoport, Inc. sits in the small-cap segment of the market. Relative to its peer group, CYRX's quantitative score of 40/100 is below the peer average of 55/100.

Quarterly Financial Performance: Cryoport, Inc.

Revenue for Cryoport, Inc. came in at $47.8M during Q1 2026, a 5.2% improvement versus the preceding quarter. The company recorded a net loss of $9.4M, with diluted EPS of $-0.23. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Industrials company. Across the four most recent quarters, CYRX averaged $0.36 in diluted EPS.

F-Score 5/9Financial Health

Cryoport, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.95 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Cryoport, Inc. revenue of about $194.4M for fiscal 2026, with EPS near $-0.78. The estimate reflects 6 contributing analysts.

CYRX Financials

CYRX Latest News

No recent news available for CYRX.

CYRX Analyst Consensus

CYRX MoonshotScore

CYRX Industrials Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources